Wat it nijste kankerûndersyk werklik ûntdekt
December 31, 2025 · Frisian News
Recent studies show cancer survival rates have stalled in many developed countries, while researchers shift focus from miracle cures to understanding why prevention efforts fail. The gap between rich and poor patients grows wider, suggesting wealth matters more than the latest treatments.
FryskDe Amerikaanske Kankermaatskippij publisearre har jierferslach yn oktober, en de koppen rjochten har op in beskieden ôfname fan trije persint yn kankerdeaden oer de ôfrûne trije desennia. Wat de koppen misten, is wichtiger: dy foarútgong is ta stilstân kommen. Oerlibingspersintaazjes binne sûnt sawat 2015 stabilisearre foar de measte kankersoarten yn wolstelde lannen, nettsjinsteande miljarden útjûn oan nij medisynûndersyk en iere opspoaring.
In grut diel fan de stagnearring komt út in ienfâldich feit dat ûndersikers no iepentlik erkenne. De minsken dy't it measte profitearje fan nije behannelingsmetoaden, binne dejingen mei jild, oplieding en tagong ta spesjalisten yn grutte stêden. In persoan dy't 200.000 dollar yn it jier fertsjinnet yn New York hat bettere kânsen as in fabryksarbeider op it plattelân fan Michigan mei deselde diagnoaze. De kleau yn oerlibingspersintaazjes nei fiif jier tusken wolstelde en earme mienskippen is tanommen ta hast tweintich persint foar guon kankersoarten. Nije medisinen binne folle minder wichtich as geografy en bankrekken.
Ûndersikers rjochtsje harren hieltyd mear op wêrom't previnsjeprogramma's mislearre binne. Rôksifers daalden sterk nei 1990, mar longkankergefallen bliuwe taai heech ûnder wurkjende Amerikaners, foaral yn Appalachia en de Rust Belt. Dieet- en obesitasyntervinsjes litte hast gjin effekt sjen. In onkolooch fan Johns Hopkins fertelde ús iepentlik: wy jouwe tachtich persint fan it kankerûndersyksjild út oan behanneling en tweintich persint oan it begripen wêrom't minsken siik wurde. Dy rekkensom kloppet net.
De farmaseutyske yndustry bliuwt djoere immunoterapyen en rjochte genêsmiddels as trochbraken op 'e merke sette, en se helpe guon pasjinten. Mar se helpe elk jier minder minsken, en de kosten per libbensjier rinne hieltyd fierder op. Medicare betellet no mear as 200.000 dollar om it libben fan in kankerpasjint seis moannen te ferlingjen mei guon nijere middels. Dat jild soe tsientallen kankergefallen foarkomme kinne as it bestege waard oan wetterkwaliteit, feiligens op it wurk of griene romte yn 'e buert.
Ynstellingen jouwe de foarkar oan ynnovaasjesferhalen om't se donateurs en media-omtinken lûke. Previnsje klinkt net nijsgjirrich. In politikus kin gjin lint trochnijen by in nij skriningssintrûm en de oerwinning opeaskje lykas hy of sy in ûndersyksbeurs oankundigje kin. It gefolch: kankerûndersyk giet foarút wylst kankersifers weromrinne, foaral yn mienskippen dy't help it meast nedich hawwe.
The American Cancer Society released its annual report in October, and the headlines focused on a modest three percent drop in cancer deaths over the past three decades. What the headlines missed matters more: that progress stopped. Survival rates have plateaued since around 2015 for most cancer types in wealthy nations, despite billions spent on new drug research and early detection programs.
Much of the stall stems from a simple fact researchers now admit openly. The people who benefit most from new treatments are those with money, education, and access to specialists in major cities. A person earning 200,000 dollars a year in New York faces better odds than a factory worker in rural Michigan with the same diagnosis. The gap in five-year survival rates between wealthy and poor communities has widened to nearly twenty percent for some cancers. New drugs matter far less than geography and bank balance.
Researchers increasingly focus on why prevention campaigns have failed. Smoking rates dropped sharply after 1990, yet lung cancer cases remain stubbornly high among working-class Americans, particularly in Appalachia and the Rust Belt. Diet and obesity interventions show almost no effect. One oncologist at Johns Hopkins told us plainly: we spend eighty percent of cancer research money on treatment and twenty percent on understanding why people get sick in the first place. That math is backwards.
The pharmaceutical industry continues to market expensive immunotherapies and targeted drugs as breakthroughs, and they help some patients. But they help a smaller number each year, and the cost per life-year gained keeps rising. Medicare now spends over 200,000 dollars to extend a cancer patient's life by six months with some newer agents. That money could prevent dozens of cancers if spent on water quality, workplace safety, or neighborhood green space.
Institutions prefer innovation stories because they attract donors and media attention. Prevention sounds unglamorous. A politician cannot cut a ribbon at a new screening center and claim victory the way she can announce a research grant. The result: cancer research marches forward while cancer rates march backward, especially in communities that need help most.
Published December 31, 2025 · Frisian News · Ljouwert, Fryslân